Get the Stockscreener App
39.62
0.70%
-0.28
After Hours:
39.62
Livanova Plc stock is traded at $39.62, with a volume of 545.34K.
It is down -0.70% in the last 24 hours and down -3.20% over the past month.
UK-based LivaNova was born of a combination between Cyberonics in the us and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the us market, another 21% from Europe, and the remainder from the rest of the world.
See More
Previous Close:
$39.90
Open:
$39.73
24h Volume:
545.34K
Relative Volume:
0.91
Market Cap:
$2.15B
Revenue:
$1.24B
Net Income/Loss:
$23.68M
P/E Ratio:
94.33
EPS:
0.42
Net Cash Flow:
$108.67M
1W Performance:
-2.00%
1M Performance:
-3.20%
6M Performance:
-24.56%
1Y Performance:
-29.09%
1-Day Range:
$39.39
$40.30
1-Week Range:
$39.16
$40.89
52-Week Range:
$36.85
$64.47
Livanova Plc Stock (LIVN) Company Profile
Name
Livanova Plc
Sector
Industry
Phone
4402033250662
Address
20 EASTBOURNE TERRACE, LONDON
Compare LIVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LIVN
Livanova Plc
|
39.62 | 2.15B | 1.24B | 23.68M | 108.67M | 0.42 |
|
ABT
Abbott Laboratories
|
131.35 | 227.80B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
100.80 | 149.09B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
367.54 | 142.81B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
88.98 | 114.12B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.19 | 41.85B | 5.72B | 4.17B | 259.90M | 6.97 |
Livanova Plc Stock (LIVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Oct-04-24 | Initiated | Goldman | Buy |
| Sep-17-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-20-24 | Reiterated | Needham | Buy |
| Feb-20-24 | Upgrade | Mizuho | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Hold |
| Jul-19-23 | Initiated | Robert W. Baird | Neutral |
| Apr-14-23 | Initiated | Mizuho | Neutral |
| Dec-21-22 | Initiated | Barclays | Equal Weight |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Feb-24-22 | Upgrade | UBS | Neutral → Buy |
| Dec-03-21 | Initiated | Goldman | Buy |
| Aug-20-21 | Reiterated | Needham | Buy |
| Jul-20-21 | Upgrade | Needham | Hold → Buy |
| Mar-03-21 | Downgrade | Berenberg | Buy → Hold |
| Jan-05-21 | Downgrade | Needham | Buy → Hold |
| Sep-02-20 | Initiated | Robert W. Baird | Outperform |
| Jun-26-20 | Reiterated | Needham | Buy |
| Oct-30-19 | Reiterated | Needham | Buy |
| Feb-28-19 | Reiterated | Needham | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Aug-02-18 | Reiterated | Needham | Buy |
| Jun-08-18 | Initiated | Stifel | Buy |
| May-31-18 | Reiterated | Needham | Buy |
| Feb-28-18 | Reiterated | Needham | Buy |
View All
Livanova Plc Stock (LIVN) Latest News
LivaNova to Announce First-Quarter 2025 Results - Business Wire
LivaNova (NASDAQ:LIVN) investors are sitting on a loss of 50% if they invested three years ago - Yahoo Finance
Should You Think About Buying LivaNova PLC (NASDAQ:LIVN) Now? - Simply Wall St
LivaNova PLC (LIVN) Shares Up 0.4% on Mar 19 - GuruFocus.com
Vagus Nerve Stimulators Market is Expected to Witness Positive - openPR
Jefferies cuts Livanova stock price target to $74 from $80 - Investing.com India
Barclays maintains Livanova stock with $56 target, cites clarity By Investing.com - Investing.com South Africa
Jefferies cuts Livanova stock price target to $74 from $80 By Investing.com - Investing.com Australia
LivaNova to record $363 million liability after court ruling By Investing.com - Investing.com Australia
Needham maintains Livanova buy rating, $64 target amid liability By Investing.com - Investing.com Australia
Barclays Maintains Livanova (LIVN) at Equalweight - StreetInsider.com
Barclays Starts Livanova (LIVN) at Equalweight - StreetInsider.com
Needham maintains Livanova buy rating, $64 target amid liability - Investing.com
LivaNova to record $363 million liability after court ruling - Investing.com
LivaNova Faces €333 Million Liability Ruling - TipRanks
Supreme Court Rules LivaNova Not Liable For 157 Mln Euros Payments In Environmental Liabilities Case - Marketscreener.com
LivaNova PLC (NASDAQ:LIVN) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
LivaNova’s SWOT analysis: medical tech firm’s stock faces growth and legal hurdles - Investing.com Australia
Cardiovascular Devices Market Booming with Technological - openPR
Autotransfusion Devices and Consumables Market is Estimated - openPR
LivaNova’s SWOT analysis: medical tech firm’s stock faces growth and legal hurdles By Investing.com - Investing.com South Africa
LivaNova PLC (NASDAQ:LIVN) Shares Sold by Bank of New York Mellon Corp - Defense World
Vagus Nerve Stimulators Market Generated Opportunities, - openPR
LivaNova at Barclays Conference: Strategic Growth and Innovation By Investing.com - Investing.com South Africa
LivaNova at Barclays Conference: Strategic Growth and Innovation - Investing.com India
When the Price of (LIVN) Talks, People Listen - Stock Traders Daily
Goldman Sachs maintains Livanova buy rating, $55 target By Investing.com - Investing.com UK
Barclays Cuts LivaNova (NASDAQ:LIVN) Price Target to $56.00 - Defense World
Mutual of America Capital Management LLC Sells 663 Shares of LivaNova PLC (NASDAQ:LIVN) - Defense World
Livanova PLC to Host Earnings Call - ACCESS Newswire
LivaNova stock hits 52-week low at $40.36 amid market challenges - Investing.com Australia
LivaNova stock hits 52-week low at $40.36 amid market challenges By Investing.com - Investing.com South Africa
Medical Implants Market Set to Witness Significant Growth by 2025-2032: Biotronik, Inc., Livanova Plc, - EIN News
LivaNova's (NASDAQ:LIVN) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance
Latin America Vagus Nerve Stimulation Market Report, 2030 - Grand View Research
Is LivaNova PLC (LIVN) the Best Medical Technology Stock to Buy According to Analysts? - Insider Monkey
After M&A Boondoggles, Livanova Refocuses on Core Businesses - Morningstar
LivaNova (NASDAQ:LIVN) Given New $55.00 Price Target at The Goldman Sachs Group - Defense World
Cardiac Surgery Devices Market Size, Share, Industry Trends, - openPR
LivaNova PLC (NASDAQ:LIVN) Stock Holdings Boosted by Principal Financial Group Inc. - Defense World
LivaNova (NASDAQ:LIVN) Given New $60.00 Price Target at Mizuho - MarketBeat
Needham & Company LLC Has Lowered Expectations for LivaNova (NASDAQ:LIVN) Stock Price - MarketBeat
LivaNova (NASDAQ:LIVN) Issues FY 2025 Earnings Guidance - MarketBeat
LivaNova (NASDAQ:LIVN) Cut to “Peer Perform” at Wolfe Research - Defense World
LivaNova (NASDAQ:LIVN) Hits New 12-Month LowTime to Sell? - MarketBeat
7 Best Medical Technology Stocks To Buy According To Analysts - Insider Monkey
Stifel Nicolaus Lowers LivaNova (NASDAQ:LIVN) Price Target to $60.00 - MarketBeat
LivaNova (NASDAQ:LIVN) Issues FY25 Earnings Guidance - MarketBeat
LivaNova (NASDAQ:LIVN) Stock Rating Lowered by Wolfe Research - MarketBeat
How To Trade (LIVN) - Stock Traders Daily
Decoding LivaNova PLC (LIVN): A Strategic SWOT Insight - GuruFocus.com
Livanova Plc Stock (LIVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
3.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):